User menu

Subcutaneous abatacept versus intravenous abatacept : a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

Bibliographic reference Genovese, M.C. ; Covarrubias, A. ; Leon, G. ; Mysler, E. ; Keiserman, M. ; et. al. Subcutaneous abatacept versus intravenous abatacept : a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.. In: Arthritis & Rheumatism, Vol. 63, no. 10, p. 2854-2864 (2011)
Permanent URL
  1. Bulpitt Ken J., Biologic therapies in rheumatoid arthritis, 10.1007/s11926-999-0013-5
  2. Emery P., Durez P., Dougados M., Legerton C. W., Becker J.-C., Vratsanos G., Genant H. K., Peterfy C., Mitra P., Overfield S., Qi K., Westhovens R., Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial), 10.1136/ard.2009.119016
  3. Westhovens R, Robles M, Ximenes A C, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park S-H, Genant H, Peterfy C, Becker J-C, Covucci A, Helfrick R, Bathon J, Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors, 10.1136/ard.2008.101121
  4. Genovese Mark C., Becker Jean-Claude, Schiff Michael, Luggen Michael, Sherrer Yvonne, Kremer Joel, Birbara Charles, Box Jane, Natarajan Kannan, Nuamah Isaac, Li Tracy, Aranda Richard, Hagerty David T., Dougados Maxime, Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition, 10.1056/nejmoa050524
  5. Genovese M C, Schiff M, Luggen M, Becker J-C, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M, Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy, 10.1136/ard.2007.074773
  6. Kremer Joel M., Dougados Maxime, Emery Paul, Durez Patrick, Sibilia Jean, Shergy William, Steinfeld Serge, Tindall Elizabeth, Becker Jean-Claude, Li Tracy, Nuamah Isaac F., Aranda Richard, Moreland Larry W., Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial, 10.1002/art.21201
  7. Kremer Joel M., Genant Harry K., Moreland Larry W., Russell Anthony S., Emery Paul, Abud-Mendoza Carlos, Szechinski Jacek, Li Tracy, Ge Zhiyu, Becker Jean-Claude, Westhovens Rene, Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis : A Randomized Trial, 10.7326/0003-4819-144-12-200606200-00003
  8. Kremer Joel M., Genant Harry K., Moreland Larry W., Russell Anthony S., Emery Paul, Abud-Mendoza Carlos, Szechiński Jacek, Li Tracy, Teng Julie, Becker Jean-Claude, Westhovens René, Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate, 10.1002/art.23397
  9. WESTHOVENS R., KREMER J. M., MORELAND L. W., EMERY P., RUSSELL A. S., LI T., ARANDA R., BECKER J.-C., QI K., DOUGADOS M., Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study, 10.3899/jrheum.080813
  10. Orencia (abatacept) prescribing information (2009)
  11. Corbo, Arthritis Rheum, 58, S307 (2008)
  12. Corbo, Ann Rheum Dis, 68, iii574 (2009)
  13. Nash, Arthritis Rheum, 60, S633 (2009)
  14. Nash, Ann Rheum Dis, 69, iii97 (2010)
  15. Arnett Frank C., Edworthy Steven M., Bloch Daniel A., Mcshane Dennis J., Fries James F., Cooper Norman S., Healey Louis A., Kaplan Stephen R., Liang Matthew H., Luthra Harvinder S., Medsger Thomas A., Mitchell Donald M., Neustadt David H., Pinals Robert S., Schaller Jane G., Sharp John T., Wilder Ronald L., Hunder Gene G., The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis, 10.1002/art.1780310302
  16. Hochberg Marc C., Chang Rowland W., Dwosh Isaac, Lindsey Stephen, Pincus Theodore, Wolfe Frederick, The american college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis, 10.1002/art.1780350502
  17. 2011
  18. A population pharmacokinetic and pharmacodynamic analysis for abatacept: relationship between abatacept concentrations and ACR 20 and DAS28 response (2006)
  19. Felson David T., Anderson Jennifer J., Boers Maarten, Bombardier Claire, Furst Daniel, Goldsmith Charles, Katz Linda M., Lightfoot Robert, Paulus Harold, Strand Vibeke, Tugwell Peter, Weinblatt Michael, James Williams H., Wolfe Frederick, Kieszak Stephanie, American college of rheumatology preliminary definition of improvement in rheumatoid arthritis, 10.1002/art.1780380602
  20. Fries James F., Spitz Patricia, Kraines R. Guy, Holman Halsted R., Measurement of patient outcome in arthritis, 10.1002/art.1780230202
  21. Prevoo M. L. L., Van'T Hof M. A., Kuper H. H., Van Leeuwen M. A., Van De Putte L. B. A., Van Riel P. L. C. M., Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis : MODIFIED DISEASE ACTIVITY SCORE, 10.1002/art.1780380107
  22. Wells, J Rheumatol, 20, 557 (1993)
  23. Kremer Joel M., Westhovens Rene, Leon Marc, Di Giorgio Eduardo, Alten Rieke, Steinfeld Serge, Russell Anthony, Dougados Maxime, Emery Paul, Nuamah Isaac F., Williams G. Rhys, Becker Jean-Claude, Hagerty David T., Moreland Larry W., Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig, 10.1056/nejmoa035075
  24. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker J-C, Lin C, Cornet P L N, Dougados M, Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate, 10.1136/ard.2007.080002
  25. European Medicines Agency 2005
  26. European Medicines Agency 1998
  27. European Medicines Agency 2000
  28. D'Agostino Ralph B., Massaro Joseph M., Sullivan Lisa M., Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics, 10.1002/sim.1425
  29. Human mixed lymphocyte reaction proliferation and cytokine production (2004)
  30. Hochberg, Arthritis Rheum, 62, S164 (2010)
  31. Humira (adalimumab) prescribing information (2011)
  32. Frenken L A, van Lier H J, Gerlag P G, den Hartog M, Koene R A, Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis., 10.1136/bmj.303.6797.288
  33. Klareskog Lars, van der Heijde Désirée, de Jager Julien P, Gough Andrew, Kalden Joachim, Malaise Michel, Mola Emilio Martín, Pavelka Karel, Sany Jacques, Settas Lucas, Wajdula Joseph, Pedersen Ronald, Fatenejad Saeed, Sanda Marie, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, 10.1016/s0140-6736(04)15640-7
  34. van Riel P L C M, Taggart A J, Sany J, Gaubitz M, Nab H W, Pedersen R, Freundlich B, MacPeek D, , Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study, 10.1136/ard.2005.043299
  35. Enbrel prescribing information (2011)
  36. Furst, J Rheumatol, 30, 2563 (2003)
  37. Radstake T R D J, Svenson M, Eijsbouts A M, van den Hoogen F H J, Enevold C, van Riel P L C M, Bendtzen K, Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis, 10.1136/ard.2008.092833
  38. Bartelds G. M., Wijbrandts C. A., Nurmohamed M. T., Stapel S., Lems W. F., Aarden L., Dijkmans B. A. C., Tak P. P., Wolbink G. J., Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study, 10.1136/ard.2009.112847
  39. Haggerty, J Rheumatol, 34, 2365 (2007)